Ribomic, Inc. (JP:4591)
:4591
Top Page
Ribomic, Inc.
(4591)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥90.00
▲(20.00% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by very weak financial performance (minimal revenue, large ongoing losses, and continued cash burn despite being debt-free). Technicals are modestly supportive with neutral-to-positive momentum and price holding around key moving averages, but valuation remains pressured by ongoing losses and lack of dividend support.
Positive Factors
Debt-free balance sheet
Zero debt lowers fixed financial obligations and default risk, preserving flexibility to fund long-duration R&D via equity, partnerships, or milestone deals. This structural strength supports sustained drug development timelines and reduces insolvency pressure common in early-stage biotech.
Negative Factors
Minimal and volatile revenue with persistent losses
Very low, inconsistent revenue and large recurring losses hamper the firm's ability to fund development internally and demonstrate commercial traction. Over the medium term this increases reliance on external funding, risks program delays, and weakens resilience to clinical or regulatory setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt lowers fixed financial obligations and default risk, preserving flexibility to fund long-duration R&D via equity, partnerships, or milestone deals. This structural strength supports sustained drug development timelines and reduces insolvency pressure common in early-stage biotech.
Read all positive factors
Ribomic, Inc. (4591) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.89B
Dividend YieldN/A
Average Volume (3M)477.44K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth-100.00%
EPS Growth7.60%
CountryJP
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.67
Shares Outstanding54,332,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.30
Price to Sales (P/S)1880.02
P/FCF Ratio-3.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ribomic, Inc. Business Overview & Revenue Model
Company Description
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart ...
How the Company Makes Money
null...
Ribomic, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 607.00K | 2.11M | 0.00 | 65.97M | 80.91M | 91.96M |
| Gross Profit | 173.00K | 1.19M | -10.50M | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.02B | -1.05B | -1.11B | -1.79B | -1.73B | -1.21B |
| Net Income | -992.53M | -1.02B | -1.02B | -1.65B | -1.68B | -1.19B |
Balance Sheet | ||||||
| Total Assets | 2.93B | 3.19B | 3.55B | 4.58B | 4.95B | 6.12B |
| Cash, Cash Equivalents and Short-Term Investments | 2.81B | 3.04B | 3.40B | 4.33B | 4.70B | 5.84B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 111.84M | 142.21M | 155.81M | 199.30M | 260.53M | 116.96M |
| Stockholders Equity | 2.82B | 3.04B | 3.39B | 4.38B | 4.69B | 6.00B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.03B | -955.48M | -1.73B | -1.51B | -1.15B |
| Operating Cash Flow | 0.00 | -996.97M | -932.76M | -1.71B | -1.50B | -1.15B |
| Investing Cash Flow | 0.00 | 67.18M | 177.27M | 276.35M | 689.56M | -1.70B |
| Financing Cash Flow | 0.00 | 667.26M | 27.65M | 1.33B | 354.72M | 4.99B |
Ribomic, Inc. Technical Analysis
Neutral
75.00
Price Trends
89.38
Positive
85.42
Positive
93.31
Negative
Market Momentum
0.12
Positive
47.54
Neutral
19.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Neutral. The current price of 75 is below the 20-day moving average (MA) of 95.25, below the 50-day MA of 89.38, and below the 200-day MA of 93.31, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 47.54 is Neutral, neither overbought nor oversold. The STOCH value of 19.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4591.
Ribomic, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | ¥11.53B | -12.44 | -26.70% | ― | 172.39% | 8.27% | |
52 Neutral | ¥5.80B | -2.65 | ― | 5.44% | -15.42% | -879.08% | |
52 Neutral | ¥137.15B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥14.77B | -17.96 | ― | ― | ― | 14.03% | |
47 Neutral | ¥4.89B | -4.17 | ― | ― | -100.00% | 7.60% | |
46 Neutral | ¥159.75B | -57.13 | -10.16% | ― | -62.47% | -134.06% |
* Healthcare Sector Average
JP:4591
Ribomic, Inc.
90.00
15.00
20.00%
JP:4587
Peptidream
1,230.50
-450.50
-26.80%
JP:4571
NanoCarrier Co., Ltd.
153.00
40.00
35.40%
JP:2183
Linical Co., Ltd.
257.00
1.88
0.74%
JP:4575
CanBas Co., Ltd.
749.00
6.00
0.81%
JP:4974
Takara Bio Inc.
1,139.00
420.00
58.41%
Ribomic, Inc. Corporate Events
RIBOMIC Files IND for Phase III Trial of Achondroplasia Drug in Japan
Mar 19, 2026
RIBOMIC has submitted an IND application to Japan’s Pharmaceuticals and Medical Devices Agency for a Phase III clinical trial of umedaptanib pegol in pediatric patients aged 2 to 14 with achondroplasia, a rare genetic disorder that causes sh...
Ribomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III
Mar 10, 2026
Ribomic reported Phase II trial results for its anti-FGF2 aptamer umedaptanib pegol in Japanese paediatric patients with achondroplasia, showing a statistically significant mean increase of 1.4 cm per year in annualized height velocity after 26 we...
RIBOMIC Posts Continued Losses but Maintains Strong Equity Base in Nine-Month Results
Feb 12, 2026
RIBOMIC Inc. reported non-consolidated results for the nine months to December 31, 2025, with operating revenue effectively at zero and a net loss of ¥763 million, though the per-share loss narrowed from ¥18.88 to ¥15.86 year on yea...
Ribomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data
Jan 14, 2026
Ribomic has filed a new substance patent application in Japan for RBM-006, a highly active anti-autotaxin aptamer with a shorter chain length than existing candidates, and reported that the molecule significantly suppressed retinal hemorrhage in a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.